{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:29:14Z","timestamp":1777922954658,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      To assess\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      ceftolozane\/tazobactam (C\/T) and ceftazidime\/avibactam (CZA) activity in beta-lactam-resistant Enterobacteriaceae and\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      clinical isolates from major carbapenem-using Departments at Montpellier University Hospital, France.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      We tested third-generation cephalosporin-resistant Enterobacteriaceae (by production of extended spectrum \u03b2-lactamase or other mechanisms, mainly AmpC beta-lactamases) and ceftazidime- and\/or carbapenem-resistant\n                      <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                      strains isolated from clinical samples of patients hospitalized from January 2017 to May 2017 and August 2016 to July 2017, respectively. We also included all OXA-48 beta-lactamase-producing Enterobacteriaceae strains isolated in the whole hospital from October 2015 to May 2017. We used the 2017 European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines for minimal inhibitory concentration interpretation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among the 62 cephalosporin-resistant Enterobacteriaceae strains, 60 (97%) were susceptible to CZA and 34 (65%) to C\/T. The two CZA-resistant\n                      <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                      isolates produced (i) NDM-carbapenemase and extended-spectrum beta-lactamase (ESBL) and (ii) ESBL CTXM-15 and OXA-1 associated with impermeability. Moreover, 31 of the 42\n                      <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                      strains (74%) were susceptible to CZA and 37 (88%) to C\/T. Finally, 26\/27 (96%) of OXA-48 beta-lactamase-producing Enterobacteriaceae were susceptible to CZA and 8\/27 (30%) to C\/T.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>At our hospital, CZA and C\/T offer a carbapenem-sparing alternative for resistant gram-negative pathogens and could be a salvage therapy for carbapenem-resistant pathogens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/mdr.2018.0439","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T09:27:15Z","timestamp":1561109235000},"page":"1325-1329","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Assessment of the\n                    <i>In Vitro<\/i>\n                    Activities of Ceftolozane\/Tazobactam and Ceftazidime\/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and\n                    <i>Pseudomonas aeruginosa<\/i>\n                    Clinical Isolates at Montpellier University Hospital, France"],"prefix":"10.1177","volume":"25","author":[{"given":"Benjamin","family":"Viala","sequence":"first","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Zohra","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilda","family":"Bastide","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Dumont","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France."},{"name":"MIVEGEC, IRD, CNRS, Universit\u00e9 de Montpellier, Montpellier, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Le Moing","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Montpellier, Montpellier, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Jean-Pierre","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France."},{"name":"MIVEGEC, IRD, CNRS, Universit\u00e9 de Montpellier, Montpellier, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Godreuil","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France."},{"name":"MIVEGEC, IRD, CNRS, Universit\u00e9 de Montpellier, Montpellier, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.08.011"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijantimicag.2017.04.001","article-title":"Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Dinh A.","year":"2017","unstructured":"Dinh A., , Wyplosz B., , Kern\u00e9is S., , Lebeaux D., , Bouchand F., , Duran C., , B\u00e9raud G., , Lazaro P., , Davido B., , H\u00e9nard S., , Canou\u00ef E., , Ferry T., , and Wolff M. 2017. Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa. Int. J. Antimicrob. Agents, 49:782\u2013783.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)","volume":"72","author":"Pfaller M.A.","year":"2017","unstructured":"Pfaller M.A., , Bassetti M., , Duncan L.R, , and Castanheira M. 2017. Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J. Antimicrob. Chemother. 72:1386\u20131395.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1128\/AAC.04218-14","article-title":"In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized \u03b2-lactamases","volume":"59","author":"Levasseur P.","year":"2015","unstructured":"Levasseur P., , Girard A.M, , Miossec C., , Pace J., , and Coleman K. 2015. In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized \u03b2-lactamases. Antimicrob. Agents Chemother. 59:1931\u20131934.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin E.","year":"2017","unstructured":"Temkin E., , Torre-Cisneros J., , Beovic B., , Benito N., , Giannella M., , Gilarranz R., , Jeremiah C., , Loeches B., , Machuca I., , Jim\u00e9nez-Mart\u00edn M.J, , Mart\u00ednez J.A, , Mora-Rillo M., , Navas E., , Osthoff M., , Pozo J.C, , Ramos Ramos J.C, , Rodriguez M., , S\u00e1nchez-Garc\u00eda M., , Viale P., , Wolff M., , and Carmelia Y. 2017. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob. Agents Chemother. 61.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp498"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00108-14","article-title":"Intestinal carriage of carbapenemase-producing organisms: current status of surveillance methods","volume":"29","author":"Viau R.","year":"2016","unstructured":"Viau R., , Frank K.M, , Jacobs M.R, , Wilson B., , Kaye K., , Donskey C.J, , Perez F., , Endimiani A., , and Bonomo R.A. 2016. Intestinal carriage of carbapenemase-producing organisms: current status of surveillance methods. Clin. Microbiol. Rev. 29:1\u201327.","journal-title":"Clin. Microbiol. Rev"},{"key":"e_1_3_4_9_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2017. Breakpoint tables for interpretation of MICs and zone diameters version 7.1 2017. Available at www.eucast.org\/ast_of_bacteria\/previous_versions_of_documents (accessed June2 2019)."},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae","volume":"61","author":"Haidar G.","year":"2017","unstructured":"Haidar G., , Clancy C.J, , Chen L., , Samanta P., , Shields R.K, , Kreiswirth B.N, , and Nguyen M.H. 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 61.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14787210.2017.1367666","article-title":"Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art","volume":"15","author":"Maraolo A.E.","year":"2017","unstructured":"Maraolo A.E., , Cascella M., , Corcione S., , Cuomo A., , Nappa S., , Borgia G., , De Rosa F.G, , and GentileI I. 2017. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Expert Rev. Anti Infect. Ther. 15:861\u2013871.","journal-title":"Expert Rev. Anti Infect. Ther"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries R.M.","year":"2015","unstructured":"Humphries R.M., , Yang S., , Hemarajata P., , Ward K.W, , Hindler J.A, , Miller S.A, , and Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob. Agents Chemother. 59:6605\u20136607.","journal-title":"Antimicrob. Agents Chemother"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2018.0439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2018.0439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2018.0439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:34:41Z","timestamp":1777667681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2018.0439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1089\/mdr.2018.0439"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2018.0439","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]}}}